$6.28
0.79% today
Nasdaq, Sep 03, 10:07 pm CET
ISIN
US14070B1017
Symbol
CAPR

Capricor Therapeutics, Inc. Stock price

$6.33
-1.35 17.58% 1M
-7.34 53.69% 6M
-7.47 54.13% YTD
+1.76 38.51% 1Y
+0.49 8.39% 3Y
+0.81 14.67% 5Y
-39.87 86.30% 10Y
-0.17 2.62% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+0.05 0.80%
ISIN
US14070B1017
Symbol
CAPR
Industry

Key metrics

Basic
Market capitalization
$289.4m
Enterprise Value
$170.0m
Net debt
positive
Cash
$122.8m
Shares outstanding
45.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
21.6 | 214.5
EV/Sales
12.7 | 126.0
EV/FCF
negative
P/B
2.8
Financial Health
Equity Ratio
85.3%
Return on Equity
-27.8%
ROCE
-69.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$13.4m | $1.3m
EBITDA
$-72.5m | $-103.1m
EBIT
$-73.4m | $-91.3m
Net Income
$-70.0m | $-99.7m
Free Cash Flow
$-56.4m
Growth (TTM | estimate)
Revenue
-50.7% | -93.9%
EBITDA
-152.5% | -470.1%
EBIT
-144.7% | -367.9%
Net Income
-150.4% | -146.3%
Free Cash Flow
-56.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-541.5% | -7,644.3%
EBIT
-548.2%
Net
-522.5% | -7,387.6%
Free Cash Flow
-421.0%
More
EPS
$-1.5
FCF per Share
$-1.2
Short interest
28.3%
Employees
160
Rev per Employee
$140.0k
Show more

Is Capricor Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Capricor Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Capricor Therapeutics, Inc. forecast:

15x Buy
94%
1x Hold
6%

Analyst Opinions

16 Analysts have issued a Capricor Therapeutics, Inc. forecast:

Buy
94%
Hold
6%

Financial data from Capricor Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
13 13
51% 51%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 19 19
40% 40%
142%
- Research and Development Expense 67 67
53% 53%
499%
-73 -73
153% 153%
-542%
- Depreciation and Amortization 0.89 0.89
30% 30%
7%
EBIT (Operating Income) EBIT -73 -73
145% 145%
-548%
Net Profit -70 -70
150% 150%
-523%

In millions USD.

Don't miss a Thing! We will send you all news about Capricor Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Capricor Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
about 8 hours ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Capricor To Contact Him Directly To Discuss Their Options
Neutral
GlobeNewsWire
one day ago
Investors can contact the law firm at no cost to learn more about recovering their losses
Neutral
GlobeNewsWire
one day ago
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Capricor Therapeutics, Inc. Investors of Upcoming Deadline
More Capricor Therapeutics, Inc. News

Company Profile

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.

Head office United States
CEO Linda Marbán
Employees 160
Founded 1996
Website capricor.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today